HA
HAVLF.US HAVN Life Sciences Inc
- Market cap
- USD 1.47K
- P/E
- -
- P/B
- 0.53x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2023.
Is HAVLF.US undervalued?
Graham numberThe Graham number of HAVN Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HAVN Life Sciences Inc fundamental analysis
No fundamental analysis for HAVN Life Sciences Inc yet.
HAVN Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HAVN Life Sciences Inc
HAVN Life Sciences Inc., a biotechnology company, engages in research and development of products for addressing mental health disorders. The company is developing formulations to support clinical trials addressing PTSD recovery and other trauma related disorders. It also focuses on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatment to support brain health and enhance the capabilities of the …
Full company profileHAVN Life Sciences Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
HAVN Life Sciences Inc annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 276K | 276K | - | - |
| Gross Profit | - | -4.60M | 89.7K | - | - |
| Operating Income | -40.6K | -30.4M | -9.81M | - | - |
| EBITDA | 4.56M | -14.8M | -7.40M | - | - |
| Net Income | -40.6K | -30.4M | -22.4M | - | - |
| EPS | -0.02 | -8.47 | -5.25 | - | - |
| Balance Sheet | |||||
| Total Assets | 1.94M | 14.2M | 4.06M | - | 1.38M |
| Total Liabilities | 41.1K | 1.04M | 918K | - | 540K |
| Shareholders' Equity | 1.90M | 13.2M | 3.14M | - | 838K |
| Cash & Short-term Investments | 1.62M | 9.40M | 1.06M | - | 14.0K |
| Total Debt | 456K | 456K | 389K | - | 26.2K |
| Cash Flow | |||||
| Operating Cash Flow | -75.0K | -10.4M | -7.88M | - | - |
| Capital Expenditure | 32.6K | 32.6K | 103K | 0.00 | - |
| Free Cash Flow | -75.0K | -10.5M | -7.98M | - | - |
| Ratios | |||||
| ROE | -2.1% | -230.2% | -714.6% | - | - |
| ROA | -2.1% | -213.3% | -552.9% | - | - |
| Net Profit Margin | - | -10,988.6% | -8,117.8% | - | - |
| Debt to Equity | 0.24x | 0.03x | 0.12x | - | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HAVN Life Sciences Inc dividends
HAVN Life Sciences Inc has not paid dividends in the last 4 fiscal years.
Last stock split: 1:30 on Aug 3, 2022.
Who owns HAVN Life Sciences Inc
- Insiders 3.51%
- Institutions 0.00%
- Public & others 96.50%
- Shares outstanding 14.7M
- Free float 14.2M
HAVN Life Sciences Inc company profile
- Company name
- HAVN Life Sciences Inc
- Ticker
- HAVLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- April
- Address
- 130 Brew Street, Port Moody, BC, Canada, V3H 0E3
- Phone
- 604 370 9520
- Website
- havnlife.com
About HAVN Life Sciences Inc
HAVN Life Sciences Inc., a biotechnology company, engages in research and development of products for addressing mental health disorders. The company is developing formulations to support clinical trials addressing PTSD recovery and other trauma related disorders. It also focuses on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatment to support brain health and enhance the capabilities of the mind. The company was incorporated in 2020 and is based in Port Moody, Canada.
HAVN Life Sciences Inc management
2- Mr. Tim MooreInterim CFO, CEO & Chairman · born 1959
- Ms. Jenna PozarChief Operations Officer